TMCnet News
World P2X Purinoceptor 3 (P2RX3) Therapeutics Pipeline Review 2016 - Research and MarketsResearch and Markets has announced the addition of the "P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016" report to their offering. 'P2X Purinoceptor 3 - Pipeline Review, H1 2016'; P2X Purinoceptor 3 (P2RX3) pipeline Target (News - Alert) constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities Institutes. Furthermore, the publisher says; P2X Purinoceptor 3 (P2RX3) P2X purinoceptor 3 is a protein that in humans is encoded by the P2RX3 gene. It belongs to the family of purinoceptors for ATP (News - Alert). This receptor functions as a ligand-gated ion channel and may transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes. The report 'P2X Purinoceptor 3 - Pipeline Review, H1 2016' outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Comanies / Universities. It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/rnjdgk/p2x_purinoceptor Related Topics: Central Nervous System Drugs, Liver and Kidney Disorders Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160829005782/en/ |
